Application of erythropoietin in preserving mesenchymal stem cells at room temperature

Erythropoietin is used to extend the storage time and viability of mesenchymal stem cells at room temperature, addressing the limitations of current cryopreservation methods by maintaining cell viability and reducing costs through the use of EPO in preservation agents.

CN119073302APending Publication Date: 2024-12-06WUHAN OPTICS VALLEY ZHONGYUAN PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411268357.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current cryopreserved mesenchymal stem cell preparations face issues of short storage time, rapid decline in viability, and high cost due to the use of physiological saline or compound electrolyte solutions with human serum albumin, limiting their clinical applications.

Method used

The application of erythropoietin (EPO) in preserving mesenchymal stem cells at room temperature, either alone or in combination with serum albumin, to maintain cell viability and reduce storage costs.

Benefits of technology

EPO maintains mesenchymal stem cell viability above 80% for up to 48-72 hours at room temperature, reducing costs and minimizing the risk of introducing unknown pathogens, while being derived from genetically engineered pharmaceutical-grade materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119073302A_ABST
    Figure CN119073302A_ABST
Patent Text Reader

Abstract

The invention provides application of erythropoietin in preservation of mesenchymal stem cells at room temperature, and relates to the technical field of biology. According to the application, the erythropoietin is applied to room-temperature preservation of the mesenchymal stem cells, or the erythropoietin is applied to preparation of a preservation reagent for room-temperature preservation of the mesenchymal stem cells, and the preservation reagent based on the application contains the erythropoietin and serum albumin. According to the application, the problems that in the prior art, the mesenchymal stem cells are short in preservation time, rapid in motility rate reduction and high in cost under the room temperature condition are solved, and the motility rate of the mesenchymal stem cells at the room temperature is increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to an application of erythropoietin in the storage of mesenchymal stem cells at room temperature. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Mesenchymal stem cells (MSCs) are a type of multipotent stem cells that originate from the mesoderm. They are abundant and widely distributed in almost all tissues, including bone marrow, fat, blood, amniotic fluid, umbilical cord, placenta, cord blood, etc. Mesenchymal stem cells can be isolated from these tissues. Mesenchymal stem cells have the characteristics of self-replication, low immunogenicity, high activity, inflammatory tendency and non-tumor formation. They can differentiate into a variety of mesenchymal tissue cells such as bone, cartilage, fat, nerve, liver, myocardium, endothelium, etc., and have strong immune regulation function. Due to their characteristics, mesenchymal stem cells have become one of the potential stocks for the treatment of many clinical diseases.

[0004] Current cryopreserved mesenchymal stem cell preparations usually use physiological saline or compound electrolyte solution containing human serum albumin as the preparation formula for clinical use of mesenchymal stem cells. The storage time is short, the cell viability decreases rapidly, and the storage conditions of the cells after resuscitation are required to be high. The limited resources and high cost of human serum albumin restrict the promotion of mesenchymal stem cell preparations in clinical applications. Therefore, how to improve the short storage time, rapid decline in viability and high cost of mesenchymal stem cell preparations is an urgent problem to be solved.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide an application of erythropoietin in the storage of mesenchymal stem cells at room temperature, so as to alleviate the problems of short storage time, rapid decline in viability and high cost of mesenchymal stem cells under room temperature in the prior art.

[0007] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0008] In a first aspect, a use of erythropoietin in preserving mesenchymal stem cells at room temperature or in preparing a preservation agent for preserving mesenchymal stem cells at room temperature is provided.

[0009] In a second aspect, a preservation reagent for preserving mesenchymal stem cells at room temperature is also provided, wherein the preservation reagent contains erythropoietin and serum albumin.

[0010] In a third aspect, a method for preserving mesenchymal stem cells is provided, the method comprising preserving the mesenchymal stem cells in a preservation agent containing erythropoietin at a storage temperature of 10 to 40°C.

[0011] In a fourth aspect, a mesenchymal stem cell preparation is provided, which contains mesenchymal stem cells and the preservation agent of the second aspect.

[0012] Compared with the prior art, the present invention has the following beneficial effects:

[0013] The present invention applies erythropoietin to mesenchymal stem cells stored at room temperature, which can maintain the cell viability of more than 80% for 48 hours, and in the preferred embodiment, it can reach 72 hours. Erythropoietin helps to store and transport mesenchymal stem cells at room temperature, reducing the cost of storage and transportation. In addition, erythropoietin can be derived from genetically engineered pharmaceutical-grade raw materials and auxiliary materials, with clear ingredients and low prices, reducing the risk of introducing unknown pathogens in the clinical use of mesenchymal stem cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0015] Figure 1 This is the curve of the cell viability of experimental groups A1 to A4 changing with time in effect example 1;

[0016] Figure 2 This is the curve of the cell viability of experimental groups B1 to B4 changing with time in effect example 1;

[0017] Figure 3 This is the curve of the apoptosis activity of experimental groups A1 to A4 changing with time in effect example 1;

[0018] Figure 4 This is the curve of the apoptosis activity rate of experimental groups B1 to B4 changing with time in effect example 1;

[0019] Figure 5 This is the curve of the cell viability of experimental groups C1 to C5 changing with time in effect example 2;

[0020] Figure 6 This is the curve of the cell viability of the experimental groups D1 to D5 changing with time in effect example 2;

[0021] Figure 7This is the curve of the apoptosis activity of experimental groups C1 to C5 changing with time in effect example 2;

[0022] Figure 8 This is the curve of the apoptosis activity rate of the experimental group D1 to D5 changing with time in effect example 2;

[0023] Fig. 9 This is the curve of the cell viability of experimental groups E1 to E4 changing with time in effect example 3;

[0024] Fig.10 This is the curve of the cell viability of experimental groups F1 to F4 changing with time in effect example 3;

[0025] Fig.11 This is the curve of the apoptotic activity rate of experimental groups E1 to E4 in effect example 3 over time;

[0026] Fig.12 This is the curve of the apoptosis activity of experimental groups F1 to F4 changing with time in effect example 3;

[0027] Fig.13 This is the curve of the cell viability of experimental groups G1 to G6 in effect example 4 over time;

[0028] Fig.14 This is the curve of the cell viability of experimental groups H1 to H5 changing with time in effect example 4;

[0029] Fig.15 This is the curve of the apoptosis activity of experimental groups G1 to G5 changing with time in effect example 1;

[0030] Fig.16 This is the curve of the apoptosis activity rate of the experimental groups H1 to H5 in effect example 1 changing with time. DETAILED DESCRIPTION

[0031] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] As used herein, "prepared from" is synonymous with "comprising". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.

[0033] As used herein, the conjunction "consisting of excludes any unspecified elements, steps or components. If used in a claim, this phrase will render the claim closed such that it excludes materials other than those described, except for normal impurities associated therewith.

[0034] Herein, when an amount, concentration, or other value or parameter is expressed as a range, a preferred range, or a range defined by a series of upper preferred values ​​and lower preferred values, this should be understood to specifically disclose all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when a range of "1 to 5" is disclosed, the described range should be interpreted as including ranges "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5", etc. When a numerical range is described herein, unless otherwise stated, the range is intended to include its end values ​​and all integers and fractions within the range.

[0035] As used herein, "and / or" is used to indicate that one or both of the described situations may occur, for example, A and / or B includes (A and B) and (A or B).

[0036] Herein, physiological saline refers to an aqueous solution whose main component is sodium chloride (NaCl), which may also contain other additives acceptable in the art to produce reagents derived from physiological saline, such as physiological saline containing glucose and / or potassium ions.

[0037] Herein, compound electrolyte solution refers to a solution containing multiple electrolytes (such as sodium, potassium, chlorine, calcium, magnesium, etc.) and glucose or gluconate, which has the effect of replenishing body fluids and restoring or maintaining electrolyte balance. Compound electrolyte solution herein includes any compound electrolyte solution and compound electrolyte injection acceptable in the art. In an optional embodiment, compound electrolyte solution is a compound electrolyte injection, which consists of 5.26g sodium chloride, 5.02g sodium gluconate, 3.68g sodium acetate, 0.37g potassium chloride and 0.30g magnesium chloride per 1000mL.

[0038] Herein, room temperature refers to a temperature condition of 10 to 40°C; in an optional embodiment, it refers to a temperature condition of 20 to 30°C; in a further optional embodiment, it refers to a temperature condition of 23 to 27°C.

[0039] In a first aspect, a use of erythropoietin in preserving mesenchymal stem cells at room temperature or in preparing a preservation agent for preserving mesenchymal stem cells at room temperature is provided.

[0040] Erythropoietin (EPO) is a hormone that helps promote the production of red blood cells. Most of EPO is produced in the kidneys, and then acts on erythroblast progenitor cells in the bone marrow, promoting the production, differentiation and proliferation of red blood cells. It also has anti-inflammatory, anti-oxidative, anti-apoptotic and angiogenesis-promoting effects in various tissues.

[0041] In an optional embodiment, the mesenchymal stem cells are stored in a storage reagent containing 10 to 100 IU / mL EPO, and the concentration of EPO in the storage reagent can be, for example, but not limited to, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 IU / mL, preferably 100 IU / mL.

[0042] In an optional embodiment, the preservation reagent further contains serum albumin.

[0043] In an optional embodiment, the preservation reagent contains 1-5% wt serum albumin, and the concentration of serum albumin can be, for example, but not limited to, 1, 2, 3, 4 or 5% wt.

[0044] In an optional embodiment, the preservation reagent further contains a solvent, and the solvent can be selected from any buffered or non-buffered single or compound solution acceptable in the art.

[0045] In an optional embodiment, the solvent includes physiological saline and / or a composite electrolyte solution.

[0046] In an optional embodiment, the room temperature is 10-40°C, for example, but not limited to 10, 12, 15, 18, 20, 22, 23, 25, 27, 28, 30, 35, 37 or 40°C, preferably 20-30°C, and more preferably 23-27°C.

[0047] In an optional embodiment, the density of mesenchymal stem cells in the storage agent is 1 to 20×10 6 / mL, for example, it can be but not limited to 1×10 6 , 2×10 6 , 2.5×10 6 , 5×10 6 , 8×10 6 , 10×10 6 , 12×10 6 , 15×10 6 , 18×10 6 or 20×10 6 Pieces / mL.

[0048] In an optional embodiment, the source of the mesenchymal stem cells includes umbilical cord, fat, bone marrow, hair follicle, dental pulp or placental tissue.

[0049] In an optional embodiment, the mesenchymal stem cells are derived from mammals, including but not limited to humans, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, goats, sheep, cows, pigs, horses or monkeys.

[0050] In an alternative embodiment, the serum albumin and the mesenchymal stem cells are derived from the same species.

[0051] In an optional embodiment, the serum albumin comprises human serum albumin.

[0052] In a second aspect, a preservation reagent for preserving mesenchymal stem cells at room temperature is also provided, wherein the preservation reagent contains EPO and serum albumin.

[0053] In an optional embodiment, the concentration of EPO is 10 to 100 IU / mL, for example, but not limited to, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 IU / mL, preferably 100 IU / mL.

[0054] In an optional embodiment, the concentration of serum albumin is 1-5% wt, for example, but not limited to, 1, 2, 3, 4 or 5% wt.

[0055] In an optional embodiment, the preservation reagent further contains a solvent, and the solvent can be selected from any buffered or non-buffered single or compound solution acceptable in the art.

[0056] In an optional embodiment, the solvent includes physiological saline and / or a composite electrolyte solution.

[0057] In an optional embodiment, the preservation reagent includes EPO 10-100 IU / mL, human serum albumin 1-5% wt and solvent 7.4-9.9 mL, and the solvent is physiological saline and / or a compound electrolyte solution.

[0058] In a third aspect, a method for preserving mesenchymal stem cells is provided, the method comprising preserving the mesenchymal stem cells in a preservation agent containing EPO at a storage temperature of 10 to 40°C.

[0059] In an optional embodiment, the storage temperature may be, for example but not limited to, 10, 12, 15, 18, 20, 22, 23, 25, 27, 28, 30, 35, 37 or 40°C, preferably 20-30°C, and more preferably 23-27°C.

[0060] In an optional embodiment, the density of mesenchymal stem cells in the storage agent is 1 to 20×10 6 / mL, for example, it can be but not limited to 1×10 6 , 2×10 6 , 2.5×10 6 , 5×10 6 , 8×10 6 , 10×10 6 , 12×10 6 , 15×10 6 , 18×10 6 or 20×10 6 Pieces / mL.

[0061] In an optional embodiment, the source of the mesenchymal stem cells includes umbilical cord, fat, bone marrow, hair follicle, dental pulp or placental tissue.

[0062] In an optional embodiment, the mesenchymal stem cells are derived from mammals, including but not limited to humans, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, goats, sheep, cows, pigs, horses or monkeys.

[0063] In an optional embodiment, the mesenchymal stem cells are preserved using the preservation reagent described in the second aspect.

[0064] In a fourth aspect, a mesenchymal stem cell preparation is provided, which contains mesenchymal stem cells and the preservation agent described in the second aspect.

[0065] In an optional embodiment, the density of mesenchymal stem cells in the storage agent is 1 to 20×10 6 / mL, for example, it can be but not limited to 1×10 6 , 2×10 6 , 2.5×10 6 , 5×10 6 , 8×10 6 , 10×10 6 , 12×10 6 , 15×10 6 , 18×10 6 or 20×10 6 Pieces / mL.

[0066] In an optional embodiment, the source of the mesenchymal stem cells includes umbilical cord, fat, bone marrow, hair follicle, dental pulp or placental tissue.

[0067] In an optional embodiment, any of the above embodiments is for non-diagnostic and non-therapeutic purposes.

[0068] In an optional embodiment, the EPO, serum albumin, compound electrolyte solution and normal saline in any of the above embodiments are independently selected from pharmaceutical grade raw materials and auxiliary materials.

[0069] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0070] The mesenchymal stem cells involved in the following embodiments and comparative examples were isolated from the umbilical cord of full-term healthy newborns without congenital diseases (the newborn mothers were from the General Hospital of the Chinese People's Liberation Army, without infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS, etc., and the mothers and their families signed informed consent for the experimental research), batch number GU231011.

[0071] The specific separation and culture method is as follows: sterilize the isolated umbilical cord to obtain a sterilized umbilical cord; then clean the sterilized umbilical cord and cut it into 1-2 cm small segments to obtain umbilical cord small segments; then cut the umbilical cord small segments into 1-2 mm 3 For tissue blocks, umbilical cord tissue blocks were cultured in a complete culture medium with fetal bovine serum (90% DMEM / F12 culture medium + 10% FBS) at 5% CO2 and 37°C. After the mesenchymal stem cells crawled out, they were subcultured to the P2 generation and cryopreserved. After the P2 generation was revived, they were subcultured using a serum-free culture medium for mesenchymal stem cells and cryopreserved to the P4 generation.

[0072] Preparation of human umbilical cord-derived mesenchymal stem cells:

[0073] P4 cell recovery: Take P4 cells frozen in liquid nitrogen and recover them. 2 The cells were inoculated at a density of 100 μg / mL into culture flasks, and serum-free complete medium was added to each flask to a standard volume (T182: 35 mL). After marking, the flasks were placed in a 5% CO2, 37°C incubator to continue P5 cell culture.

[0074] Observe the cells under the microscope every day. When the cell fusion reaches 60% to 80% 48 to 72 hours after inoculation, digest and harvest the cells. Aspirate the culture medium in all culture bottles. Add an appropriate amount of PBS to each culture bottle and wash it once, then add TrypLE to digest for about 2 minutes. After the cells are completely suspended, add PBS to terminate the digestion. Transfer the cell suspension to a 50mL centrifuge tube. Wash each culture bottle with PBS again, transfer the washed cell suspension into a centrifuge tube, and centrifuge at 300g for 5 minutes. Wash twice with 0.9% sodium chloride, then pass through a 100μm cell sieve to remove cell clumps, fill according to the specification of 5E7, 10ml / bag, and store in liquid nitrogen with program-controlled cooling.

[0075] In the following examples and comparative examples, the concentration of human serum albumin is expressed in mass percentage.

[0076] Example 1

[0077] Provided is a MSCs preservation reagent comprising a compound electrolyte solution and 10 IU / ml EPO.

[0078] Example 2

[0079] Provided is a MSCs preservation reagent comprising a compound electrolyte solution and 50 IU / ml EPO.

[0080] Example 3

[0081] Provided is a MSCs preservation reagent comprising a compound electrolyte solution and 100 IU / ml EPO.

[0082] Example 4

[0083] Provided is a MSCs preservation reagent containing physiological saline and 10 IU / ml EPO.

[0084] Example 5

[0085] Provided is a MSCs preservation reagent containing physiological saline and 50 IU / ml EPO.

[0086] Example 6

[0087] Provided is a MSCs preservation reagent containing physiological saline and 100 IU / ml EPO.

[0088] Example 7

[0089] Provided is a MSCs preservation reagent containing a compound electrolyte solution, 1% human serum albumin and 10 IU / ml EPO.

[0090] Example 8

[0091] Provided is a MSCs preservation reagent containing a compound electrolyte solution, 1% human serum albumin and 50 IU / ml EPO.

[0092] Example 9

[0093] Provided is a MSCs preservation reagent containing a compound electrolyte solution, 1% human serum albumin and 100 IU / ml EPO.

[0094] Example 10

[0095] Provided is a MSCs preservation reagent containing physiological saline, 1% human serum albumin and 10 IU / ml EPO.

[0096] Embodiment 11

[0097] Provided is a MSCs preservation reagent containing physiological saline, 1% human serum albumin and 50 IU / ml EPO.

[0098] Example 12

[0099] Provided is a MSCs preservation reagent containing physiological saline, 1% human serum albumin and 100 IU / ml EPO.

[0100] Comparative Example 1

[0101] Provided is a MSCs preservation reagent, which is a compound electrolyte solution.

[0102] Comparative Example 2

[0103] Provided is a MSCs preservation reagent, which is physiological saline.

[0104] Comparative Example 3

[0105] Provided is a MSCs preservation reagent containing a compound electrolyte solution and 1% human serum albumin.

[0106] Comparative Example 4

[0107] Provided is a MSCs preservation reagent containing a compound electrolyte solution and 5% human serum albumin.

[0108] Comparative Example 5

[0109] Provided is a MSCs preservation reagent containing physiological saline and 1% human serum albumin.

[0110] Comparative Example 6

[0111] Provided is a MSCs preservation reagent containing physiological saline and 5% human serum albumin.

[0112] Effect Example 1

[0113] The ability of the MSCs preservation reagents provided in Comparative Examples 1 and 2 and Examples 1 to 6 to preserve MSCs cells at 25±2°C was compared, and the experimental groups were shown in Table 1:

[0114] Table 1 Effect Example 1 Experimental Grouping

[0115]

[0116] Experimental methods:

[0117] (1) Cell viability detection

[0118] Take out the frozen cells, quickly re-dissolve them in a 37°C water bath, prepare the cell preparation according to the formula in Table 1, and resuspend the revived cells in each preservation reagent in Table 1. The cell density is 5×10 6 / ml. Samples were taken at 0h, 24h, 48h, and 72h for cell viability detection, and the storage condition was 25±2℃. The sample cells were resuspended and mixed evenly, 20μl of cell suspension was taken and mixed evenly with 20μl of AO / PI fluorescent dye, 20μl was added to the Countstar counting plate, the cell type was selected as "MSC", the counting mode was selected as "AO / PI counting", and the fluorescence counter was used for counting, and repeated 3 times.

[0119] (2) Cell apoptosis detection

[0120] Wash the experimental samples in step (1) once with pre-cooled PBS, centrifuge at 300g for 5 minutes, discard the supernatant, mix the cells with 400μL 1×Binding Buffer, and divide them equally into 4 flow tubes, which are respectively recorded as blank tube, Annexin V single staining tube, 7-AAD single staining tube, and Annexin V and 7-AAD double staining tube. Annexin V single staining tube: add 2μL Annexin V antibody to each tube. 7-AAD single staining tube: add 5μL 7-AAD antibody to each tube. Annexin V and 7-AAD double staining tube: add 2μL Annexin V antibody and 5μL 7-AAD antibody to each tube. Incubate at room temperature in the dark for 15 minutes, add 400μL 1×Binding Buffer to each tube, mix well and load on the machine. The experimental results were analyzed using FlowJo.

[0121] Experimental results:

[0122] The results are shown in Tables 2 to 5 and Figure 1 to Figure 4 As shown, using physiological saline or compound electrolytes as preservation reagents, the cell viability can only be preserved for 24 hours at room temperature with a viability of more than 80%, while the preservation of cells in a preservation reagent containing 100 IU / ml EPO can extend the preservation of cell viability to 48 hours with a viability of more than 80%. The above results show that EPO as a preservation reagent for mesenchymal stem cells can significantly prolong the preservation time and preservation effect of mesenchymal stem cells at room temperature.

[0123] Table 2. Cell viability results of experimental groups A1 to A4

[0124]

[0125] Table 3. Results of cell viability in experimental groups B1 to B4

[0126]

[0127] Table 4. Results of apoptosis activity of cells in experimental groups A1 to A4

[0128]

[0129] Table 5. Results of apoptosis activity of cells B1 to B4 in experimental groups

[0130]

[0131] Effect Example 2

[0132] Comparison of the ability of the MSCs preservation reagents provided in Comparative Examples 3 to 6 and Examples 1 to 6 to preserve MSCs cells at 25±2°C, the experimental groups are shown in Table 6:

[0133] Table 6 Effect Example 2 Experimental Grouping

[0134]

[0135] The experimental method is the same as that of Example 1.

[0136] Experimental results:

[0137] The results are shown in Tables 7 to 10 and Figures 5 to 8 As shown, using physiological saline or compound electrolytes containing 1% and 5% human serum albumin as a preservation agent, the cell viability dropped below 80% just after the cells were preserved for more than 24 hours at room temperature. The physiological saline or compound electrolytes containing 10IU / ml and 50IU / ml EPO as a preservation agent have a similar cell preservation effect to the cell preparation formula containing human serum albumin. At room temperature, the cell viability can only be maintained above 80% for 24 hours; while the cell preparation formula containing 100IU / ml EPO can preserve cells and maintain the cell viability above 80%, which can be extended to 48 hours. By comparing the above experimental results, it can be seen that the preservation agent containing 100IU / ml EPO has a good cell preservation effect.

[0138] Table 7. Results of cell viability of experimental groups C1 to C5

[0139]

[0140] Table 8. Results of cell viability in experimental groups D1 to D5

[0141]

[0142]

[0143] Table 9. Apoptosis results of C1-C5 cells in the experimental group

[0144]

[0145] Table 10. Cell apoptosis results of experimental groups D1 to D5

[0146]

[0147] Effect Example 3

[0148] Comparison of the ability of the MSCs preservation reagents provided in Comparative Examples 3 and 5 and Examples 7 to 12 to preserve MSCs cells at 25±2°C, the experimental groups are shown in Table 11:

[0149] Table 11. Experimental grouping of effect example 3

[0150]

[0151] The experimental method is the same as that of Example 1.

[0152] Experimental results:

[0153] The results are shown in Tables 12 to 15 and Figures 9 to 12 As shown in the figure, compared with the preservation reagent using 1% human serum albumin alone, by adding different concentrations of EPO on this basis, the cell viability is maintained longer at room temperature. Among them, the preservation reagent containing a final concentration of 1% human serum albumin and 10IU / ml EPO can maintain the cell viability above 80% for 48 hours. The preservation reagent containing a final concentration of 1% human serum albumin and 50 or 100IU / ml EPO and a compound electrolyte can maintain the cell viability above 80% and even extend it to 72 hours.

[0154] Table 12. Results of cell viability in experimental groups E1 to E4

[0155]

[0156] Table 13. Results of cell viability of experimental groups F1 to F4

[0157]

[0158] Table 14. Results of apoptosis activity of E1 to E4 cells in experimental groups

[0159]

[0160] Table 15. Results of apoptosis survival rate of F1-F4 cells in experimental groups

[0161]

[0162] Effect Example 4

[0163] The MSCs preservation reagents of Examples 9 and 12 were used to preserve cells of different densities, respectively, and the preservation conditions were 25±2° C. The experimental groups are shown in Table 16:

[0164] Table 16. Experimental grouping of effect example 4

[0165]

[0166] The experimental method is the same as that of Example 1.

[0167] Experimental results:

[0168] The results are shown in Tables 17 to 20 and Figure 13 to Figure 16 As shown in the figure, the cell viability time of cells of different densities preserved by the formula of compound electrolyte + final concentration of 1% human serum albumin + 100 IU / ml EPO and normal saline + final concentration of 1% human serum albumin + 100 IU / ml EPO was almost the same, indicating that the cell density range of the preservation reagent is 1×10 6 / ml to 2×10 7 Pieces / ml.

[0169] Table 17. Results of cell viability in experimental groups G1 to G5

[0170]

[0171] Table 18. Results of cell viability in experimental groups H1 to H5

[0172]

[0173] Table 19. Results of apoptosis activity of G1-G5 cells in experimental groups

[0174]

[0175] Table 20. Results of apoptosis activity of cells H1 to H5 in the experimental group

[0176]

[0177] The actual materials used in the above embodiments, comparative examples and effect examples are shown in Table 21:

[0178] Table 21

[0179] name factory Part Number DMEM / F12 medium BI 01-072-1A Fetal bovine serum BI 04-001-1ACS Serum-free medium for mesenchymal stem cells Youkang NC0103 Serum-free medium supplement for mesenchymal stem cells Youkang NC0103.S Compound electrolyte Baxter Healthcare National Medicine Approval No. H20000476 Sodium Chloride Injection Shijiazhuang No.4 Pharmacy National Medicine Approval No. H13023201 AO / PI Nexcelom CS2-0106-5ml TRYPLE gbico 12563029 EPO Chengdu Diao Jiuhong Pharmaceutical National Medicine Approval No. S19991005 PE Annexin V Apoptosis Detection Kit I BD 559763

[0180] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of erythropoietin in the storage of mesenchymal stem cells at room temperature, or in the preparation of a storage reagent for the storage of mesenchymal stem cells at room temperature.

2. The use according to claim 1, characterized in that: The mesenchymal stem cells are stored in a storage reagent containing 10 to 100 IU / mL erythropoietin; Optionally, the preservation reagent further contains serum albumin; Optionally, the preservation reagent contains 1-5%wt serum albumin; Optionally, the preservation reagent further contains a solvent; Optionally, the solvent includes physiological saline and / or a composite electrolyte solution.

3. The use according to claim 1 or 2, characterized in that: The room temperature is 10-40°C, optionally 20-30°C, further optionally 23-27°C; Optionally, the density of mesenchymal stem cells in the storage reagent is 1 to 20×10 6 Pieces / mL; Optionally, the source of the mesenchymal stem cells includes umbilical cord, fat, bone marrow, hair follicle, dental pulp or placental tissue; Optionally, the serum albumin and the mesenchymal stem cells are derived from the same species; Optionally, the serum albumin comprises human serum albumin.

4. A storage reagent for storing mesenchymal stem cells at room temperature, characterized in that: Contains erythropoietin and serum albumin.

5. The preservation reagent according to claim 4, characterized in that The concentration of erythropoietin is 10 to 100 IU / mL, and / or the concentration of serum albumin is 1 to 5% wt; Optionally, the concentration of erythropoietin is 100 IU / mL; Optionally, the preservation reagent further contains a solvent; Optionally, the solvent includes physiological saline and / or a composite electrolyte solution.

6. The preservation reagent according to claim 5, characterized in that It includes 10-100 IU / mL of erythropoietin, 1-5% wt of human serum albumin and 7.4-9.9 mL of solvent; The solvent is physiological saline and / or a compound electrolyte solution.

7. A method for preserving mesenchymal stem cells, characterized in that: The method comprises storing mesenchymal stem cells in a storage reagent containing erythropoietin at a storage temperature of 10 to 40°C.

8. The storage method according to claim 7, characterized in that: The storage temperature is 20-30°C, and further optionally 23-27°C; Optionally, the density of mesenchymal stem cells in the storage reagent is 1 to 20×10 6 Pieces / mL; Optionally, the mesenchymal stem cells are preserved using the preservation reagent according to any one of claims 4 to 6.

9. A mesenchymal stem cell preparation, characterized in that: Containing mesenchymal stem cells and the preservation agent according to any one of claims 4 to 6.

10. The mesenchymal stem cell preparation according to claim 9, characterized in that The density of mesenchymal stem cells in the storage reagent is 1 to 20×10 6 Pieces / mL; Optionally, the sources of the mesenchymal stem cells include umbilical cord, fat, bone marrow, hair follicle, dental pulp or placental tissue.